

McDermott Will & Emery

Boston Brussels Chicago Düsseldorf London Los Angeles Miami Milan
Munich New York Orange County Rome San Diego Silicon Valley Washington, D.C.

RECEIVED
CENTRAL FAX CENTER

JUN 18 2007

FACSIMILE

Date: June 18, 2007

Time
Sent:

To:	Company:	Facsimile No:	Telephone No:
Mail Stop: AMENDMENT	USPTO	571-273-8300	
From:	Atabak R. Royae	Direct Phone:	617.535.4108
E-Mail:	aroyae@mwe.com		
Sent By:		Direct Phone:	
Client/Matter/Tkpr:	068911-0074	Original to Follow by Mail	No
		Number of Pages, Including Cover:	12

Message:

BST99 1325996-1.068911.0060

The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copy of this facsimile is strictly prohibited. If you have received this facsimile in error, please notify us immediately by telephone and return the original message to us at the below address by mail. Thank you.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL AS SOON AS POSSIBLE.

Main Facsimile: 617.535.3800 Facsimile Operator: 617.535.4000

U.S. practice conducted through McDermott Will & Emery

28 State Street Boston, Massachusetts 02109-1775 Telephone: 617 535 4000

PAGE 1/12 * RCVD AT 6/18/2007 2:25:02 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-3/14 * DNIS:2738300 * CSID:617 535 3869 * DURATION (mm-ss):03-56

JUN 18 2007

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: J. Babish, et al.
Application No.: 10/789,817
Filing Date: February 27, 2004
Docket Number: 068911-0074
Title: SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL
COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS
OR METHYLXANTHINES
Examiner: Not yet assigned
Art Unit: 5656
Confirmation No.: 1617

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted (571) 273-8300 to the USPTO, on the date indicated below.

Date: June 18, 2007


Jacqueline I. AndreuMAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Enclosed herewith for filing in connection with the above-identified patent application are the following:


- 1) First Preliminary Amendment (10 pages)

There are no fees due with the filing of this Preliminary Amendment. However, the Commissioner is authorized to charge any further fees which may become due and/or credit any overpayment to Deposit Account Number 50-1133.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP

Dated: June 18, 2007


Atabak R. Royae, Reg. No. 59,037
McDERMOTT WILL & EMERY LLP
28 State Street
Boston, Massachusetts 02109
Telephone: (617) 535-4049
Facsimile: (617) 535-3800

BST99 1544608-1.068911.0074

RECEIVED
CENTRAL FAX CENTER

JUN 18 2007

PATENT

Attorney Docket No. 068911-0074

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

J. Babish, et al.

Application No.: 10/789,817

Filed: February 27, 2004

**For: Synergistic Anti-Inflammatory
Pharmaceutical Compositions and
Related Methods Using
Curcuminoids or Methylxanthines**

Group Art Unit: 1617

Examiner: Not Yet Assigned

Confirmation No.: 5656

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted (571) 273-8300 to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Date: June 18, 2007

Jacqueline Andreu
Jacqueline N. Andreu

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

FIRST PRELIMINARY AMENDMENT

Prior to the examination of the above application, please amend this application as follows:

Amendments to the Claims are reflected in the listing of claims in this paper at page 2.

Remarks/Arguments follow the amendment sections of this paper at page 10.